Last reviewed · How we verify

1 month of PDE5i treatment

Centre Hospitalier Universitaire de Nīmes · Phase 1 active Small molecule Quality 0/100

1 month of PDE5i treatment is a Small molecule drug developed by Centre Hospitalier Universitaire de Nīmes. It is currently in Phase 1 development.

At a glance

Generic name1 month of PDE5i treatment
SponsorCentre Hospitalier Universitaire de Nīmes
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about 1 month of PDE5i treatment

What is 1 month of PDE5i treatment?

1 month of PDE5i treatment is a Small molecule drug developed by Centre Hospitalier Universitaire de Nīmes.

Who makes 1 month of PDE5i treatment?

1 month of PDE5i treatment is developed by Centre Hospitalier Universitaire de Nīmes (see full Centre Hospitalier Universitaire de Nīmes pipeline at /company/centre-hospitalier-universitaire-de-n-mes).

What development phase is 1 month of PDE5i treatment in?

1 month of PDE5i treatment is in Phase 1.

Related